Eli Lilly to Invest $1 B in AI Lab While FDA Delays Obesity Pill Approval
Eli Lilly partnered with Nvidia to invest up to $1 billion over five years in a Bay Area AI research lab to accelerate drug discovery. The FDA reportedly delayed approval of its obesity pill orforglipron to April, potentially weighing on the company’s near-term growth.
1. Nvidia Partnership to Accelerate AI-Driven Drug Discovery
On January 12, Eli Lilly announced a collaboration with Nvidia to establish a dedicated AI research laboratory in the San Francisco Bay Area. Over the next five years, the two companies will invest up to $1 billion in construction, high-performance computing infrastructure and joint staffing. The lab will bring together Lilly’s therapeutic researchers and Nvidia’s AI engineers to build and refine machine-learning models aimed at reducing the time and cost of early-stage drug discovery. This follows Lilly’s October launch of the industry’s most powerful pharmaceutical supercomputer in partnership with Nvidia and its 2023 release of TuneLab, a free AI discovery platform for smaller biotechs—moves designed to leverage Lilly’s vast clinical-trial data and strengthen its competitive moat in computational drug design.
2. Weight-Management Leadership and Robust Late-Stage Pipeline
Lilly’s tirzepatide franchise, comprised of Mounjaro for diabetes and Zepbound for weight loss, became the world’s top-selling drug in Q3, driving a 54% year-over-year revenue increase to $17.6 billion and lifting adjusted EPS to $6.21, a 480% gain versus the prior-year period. Beyond tirzepatide, Lilly is advancing orforglipron—its oral obesity pill—through regulatory review with an expected decision by April, and its next-generation dual-agonist retatrutide is delivering promising Phase 3 obesity data. The company has also expanded into immunology, oncology and rare diseases with recent approvals of Ebglyss for eczema, Jaypirca for cancer and Kisunla for Alzheimer’s, aiming to reduce reliance on its core metabolic franchise over the coming decade.
3. Strong Cash Flow and Dividend Growth Strategy
Eli Lilly generated significant free cash flow in 2025, maintaining an industry-leading gross margin above 83% and a strong balance sheet that supports both R&D and shareholder returns. The company has increased its dividend by 103.5% over the past five years and currently yields 0.58%, reflecting a disciplined capital allocation policy. Continued pipeline advances and operating leverage from high-margin specialty medicines underpin management’s commitment to further dividend hikes and opportunistic share repurchases, offering a balanced risk-reward profile for income-oriented and growth investors alike.